Epithelial ovarian cancer: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 57: Line 57:
* Decreased anoikis
* Decreased anoikis
|-
|-
|Insulin-like growth factor/receptor ILGF/ILGFR<ref name="pmid11577173">{{cite journal |vauthors=Laron Z |title=Insulin-like growth factor 1 (IGF-1): a growth hormone |journal=MP, Mol. Pathol. |volume=54 |issue=5 |pages=311–6 |date=October 2001 |pmid=11577173 |pmc=1187088 |doi= |url=}}</ref><ref name="pmid22682634">{{cite journal |vauthors=Weroha SJ, Haluska P |title=The insulin-like growth factor system in cancer |journal=Endocrinol. Metab. Clin. North Am. |volume=41 |issue=2 |pages=335–50, vi |date=June 2012 |pmid=22682634 |pmc=3614012 |doi=10.1016/j.ecl.2012.04.014 |url=}}</ref>
|Insulin-like growth factor/receptor ILGF/ILGFR<ref name="pmid11577173">{{cite journal |vauthors=Laron Z |title=Insulin-like growth factor 1 (IGF-1): a growth hormone |journal=MP, Mol. Pathol. |volume=54 |issue=5 |pages=311–6 |date=October 2001 |pmid=11577173 |pmc=1187088 |doi= |url=}}</ref><ref name="pmid22682634">{{cite journal |vauthors=Weroha SJ, Haluska P |title=The insulin-like growth factor system in cancer |journal=Endocrinol. Metab. Clin. North Am. |volume=41 |issue=2 |pages=335–50, vi |date=June 2012 |pmid=22682634 |pmc=3614012 |doi=10.1016/j.ecl.2012.04.014 |url=}}</ref><ref name="pmid12237896">{{cite journal |vauthors=Lukanova A, Lundin E, Toniolo P, Micheli A, Akhmedkhanov A, Rinaldi S, Muti P, Lenner P, Biessy C, Krogh V, Zeleniuch-Jacquotte A, Berrino F, Hallmans G, Riboli E, Kaaks R |title=Circulating levels of insulin-like growth factor-I and risk of ovarian cancer |journal=Int. J. Cancer |volume=101 |issue=6 |pages=549–54 |date=October 2002 |pmid=12237896 |doi=10.1002/ijc.10613 |url=}}</ref>
|
|
* Promotes growth
* Promotes growth

Revision as of 16:01, 26 February 2019


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Hannan Javed, M.D.[2]

Possible genetic alteration in epithelial ovarian cancers
Protein Normal function Result of mutation
Epidermal growth factor receptor (HER-1)[1][2]
  • Promotes cell proliferation
  • Opposes apoptosis
  • Regulates differentiation
  • Activating mutation
  • Increased cellular proliferation
  • Inhibition of apoptosis
Human Epidermal Growth Factor Receptor 2 (HER-2)[1][2]
  • Promotes cell prolifeartion
  • Inhibition of apoptosis
  • Regulates differentiation
  • Activating mutation
  • Increased cellular proliferation
  • Inhibition of apoptosis
Non-receptor tyrosine kinase Src[3][4] Involved in regulation of
  • Gene transcription
  • Angiogenesis
  • Cellular adhesion
  • Cellular proliferation
  • Activating mutation
  • Increased angiogenesis
  • Decreased cellular adhesion
  • Increased tumor metastasis
  • Increased cellular proliferation
CSF-1/fms[5][6][7]
  • Increased macrophage survival
  • Increased macrophage proliferation
  • Increased macrophage differentiation
  • Activating mutation
  • Stimulation of tumor cell proliferation
  • Increased angiogenesis
  • Promotes tumor invasion
  • Increased metastasis
  • Decreased anoikis
Insulin-like growth factor/receptor ILGF/ILGFR[8][9][10]
  • Promotes growth
  • Increased survival
  • Activating mutation
  • Increased proliferation
  • Enhanced survival
  • Suppression of cell cycle regulators
k-ras
b-raf
TGF-β
myc
Cyclin D/Cdk4/6
Cyclin E/Cdk2
Cyclin B/Cdk1
p16
p27 (kip-1)
p21 (WAF-1)
NFκB
NOEY(ARHI)
PIP3/Akt
PTEN
p53
BRCA1
BRCA2
MLH1/MSH2
Fas ligand
HLA-G
hTERT
VEGF/VEGFR
IL-8
EphA2
MMPs
αvβ3
FAK
E-cadherin

References

  1. 1.0 1.1 Wee P, Wang Z (May 2017). "Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways". Cancers (Basel). 9 (5). doi:10.3390/cancers9050052. PMC 5447962. PMID 28513565.
  2. 2.0 2.1 Iqbal N, Iqbal N (2014). "Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications". Mol Biol Int. 2014: 852748. doi:10.1155/2014/852748. PMC 4170925. PMID 25276427.
  3. Zan L, Wu H, Jiang J, Zhao S, Song Y, Teng G, Li H, Jia Y, Zhou M, Zhang X, Qi J, Wang J (July 2011). "Temporal profile of Src, SSeCKS, and angiogenic factors after focal cerebral ischemia: correlations with angiogenesis and cerebral edema". Neurochem. Int. 58 (8): 872–9. doi:10.1016/j.neuint.2011.02.014. PMC 3100427. PMID 21334414.
  4. Reinecke JB, Katafiasz D, Naslavsky N, Caplan S (April 2014). "Regulation of Src trafficking and activation by the endocytic regulatory proteins MICAL-L1 and EHD1". J. Cell. Sci. 127 (Pt 8): 1684–98. doi:10.1242/jcs.133892. PMC 3986674. PMID 24481818.
  5. Saad AF, Hu W, Sood AK (December 2010). "Microenvironment and pathogenesis of epithelial ovarian cancer". Horm Cancer. 1 (6): 277–90. doi:10.1007/s12672-010-0054-2. PMC 3199131. PMID 21761359.
  6. Dwyer AR, Greenland EL, Pixley FJ (June 2017). "Promotion of Tumor Invasion by Tumor-Associated Macrophages: The Role of CSF-1-Activated Phosphatidylinositol 3 Kinase and Src Family Kinase Motility Signaling". Cancers (Basel). 9 (6). doi:10.3390/cancers9060068. PMC 5483887. PMID 28629162.
  7. Abraham D, Zins K, Sioud M, Lucas T, Schäfer R, Stanley ER, Aharinejad S (March 2010). "Stromal cell-derived CSF-1 blockade prolongs xenograft survival of CSF-1-negative neuroblastoma". Int. J. Cancer. 126 (6): 1339–52. doi:10.1002/ijc.24859. PMC 3222589. PMID 19711348.
  8. Laron Z (October 2001). "Insulin-like growth factor 1 (IGF-1): a growth hormone". MP, Mol. Pathol. 54 (5): 311–6. PMC 1187088. PMID 11577173.
  9. Weroha SJ, Haluska P (June 2012). "The insulin-like growth factor system in cancer". Endocrinol. Metab. Clin. North Am. 41 (2): 335–50, vi. doi:10.1016/j.ecl.2012.04.014. PMC 3614012. PMID 22682634.
  10. Lukanova A, Lundin E, Toniolo P, Micheli A, Akhmedkhanov A, Rinaldi S, Muti P, Lenner P, Biessy C, Krogh V, Zeleniuch-Jacquotte A, Berrino F, Hallmans G, Riboli E, Kaaks R (October 2002). "Circulating levels of insulin-like growth factor-I and risk of ovarian cancer". Int. J. Cancer. 101 (6): 549–54. doi:10.1002/ijc.10613. PMID 12237896.